Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amy Tank

Physician Assistant Hackensack, NJ Physician Assistant

NPI 1043631831 CMS profile 10715787

20 Prospect Ave Ste 702, Hackensack, NJ 07601

Open in the dashboard

General payments

$8,261

596 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Tank of Hackensack, NJ is reported in the CMS Open Payments database as having received $8,261 across 596 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,671 193
2024 General $2,087 165
2023 General $1,440 117
2022 General $1,233 73
2021 General $830 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Tank
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Amy Tank were reported at $2,671. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Amy Tank Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $830 $132 $37–$438 $132
2022 $1,233 $155 $48–$522 $149
2023 $1,440 $167 $52–$557 $160
2024 $2,087 $178 $55–$600 $164
2025 $2,671 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,037 65 payments
  2. Sun Pharmaceutical Industries Inc. $931 74 payments
  3. Janssen Biotech, Inc. $814 38 payments
  4. Incyte Corporation $726 66 payments
  5. E.R. Squibb & Sons, L.L.C. $722 74 payments
  6. Lilly USA, LLC $537 42 payments
  7. Pfizer Inc. $473 35 payments
  8. Galderma Laboratories, L.P. $455 28 payments
  9. Arcutis Biotherapeutics, Inc. $391 36 payments
  10. Novartis Pharmaceuticals Corporation $318 15 payments
  11. Other $1,857 123 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,962 593 payments
  2. Education $299 3 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $762 32 payments
  2. OPZELURA $726 66 payments
  3. SOTYKTU $722 74 payments
  4. Winlevi $627 57 payments
  5. SKYRIZI $493 27 payments
  6. TALTZ $379 28 payments
  7. LITFULO $358 27 payments
  8. CIBINQO $347 26 payments
  9. Absorica LD $324 32 payments
  10. RINVOQ $272 19 payments
  11. Other $4,781 329 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

504

Median for Physician Assistant: 241

Drug cost

$12,379

Median for Physician Assistant: $4,110

Branded share of claims

9.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Triamcinolone Acetonide Generic 109 $2,045
Clobetasol Propionate Generic 24 $1,757
Ketoconazole Generic 96 $1,735
Clindamycin Phosphate Generic 25 $1,018
Fluocinonide Generic 31 $1,013
Tretinoin Generic 14 $983
Mometasone Furoate Generic 32 $728
Mupirocin Generic 55 $594
Ciclopirox Generic 12 $521
Hydrocortisone Generic 25 $489

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$202,314

Of which drugs: $111

Medicare patients

255

Average age 71

Services billed

2,581

157 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 47%
Diabetes 29%
Ischemic heart disease 27%
Osteoporosis 20%
Depression 18%
Cancer 15%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 35 151 $111

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $336
$336 — —
TREMFYA
  • Janssen Biotech, Inc. $228
$228 — —
SKYRIZI
  • AbbVie, Inc. $204
$204 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $192
$192 — —
OPZELURA
  • Incyte Corporation $149
$149 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

596 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record